PharmiWeb.com - Global Pharma News & Resources
13-May-2019

Hardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology

Hardman & Co Research

13-May-2019 / 12:20 GMT/BST


Hardman & Co: Commercialising a breakthrough technology

Advanced Oncotherapy's (AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement of a number of technical milestones, the successful integration of all the module types that constitute the LIGHT accelerator, and acceleration of the proton beam to an energy of 52MeV, sufficient to treat superficial tumours. With LIGHT, its breakthrough PBT technology, AVO is aiming to replicate the commercial success of MRI by opening new untapped markets with an innovative financing strategy.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/commercialising-a-breakthrough-technology/

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622


mh@hardmanandco.com
dmh@hardmanandco.com
gp@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

Editor Details

Last Updated: 13-May-2019